DURHAM, N.C., SEPTEMBER 5, 2017 — Sponsors and CROs can forge stronger relationships by pursuing long-term partnerships that value collaboration over transactions. Premier Research’s top neuroscientist will discuss how when she hosts a session at Outsourcing Clinical Trials New England in Boston. Krista Armstrong, Vice President and Head of Neuroscience, will describe best practices for...
This is the third installment of our look at the increasingly high placebo response that is plaguing clinical trials in analgesia and psychiatry. Additional posts in the series can be accessed here. Solutions to the placebo problem require an understanding of the underlying mechanisms. Broadly, research on contributors to the placebo response falls into two...
This is Part Two of our series on the increasingly high placebo response that is plaguing clinical trials in analgesia and psychiatry. Read the other parts here. Analgesic and psychiatric drug development is facing an enormous problem: rising placebo responses in randomized controlled trials (RCTs) threaten the ability of pharmaceutical companies to successfully identify novel...
Sponsors often face significant challenges in collecting robust, quality data that demonstrates the safety and efficacy of investigative psychiatric drugs. However, before these problems can be solved, they must be understood. Be sure to keep these four issues in mind when mapping out strategies for ensuring quality data collection in psychiatric clinical trials. 1. There...
Although current limitations in neuropsychological testing may discourage development of treatments for central nervous system (CNS) disorders, some researchers see these unmet needs as an opportunity for innovation. Take a look at three strategies that are improving the validity and viability of neuropsychological testing. Rater Training Success or failure of a CNS trial can come down to...
Central nervous system (CNS) disorders are a diverse group of conditions that include psychiatric, neurological and substance abuse disorders. Unfortunately for patients, treatment options for CNS disorders are often limited (or non-existent). To make matters worse, comparatively few CNS drugs are in the development pipeline. What aspects of CNS disorders contribute to lagging drug development? Read on to...
When it comes to clinical trials for neurodegenerative disease (NDD), it’s easy to get overwhelmed by complexity. Not only are the mechanisms that underlie NDDs like multiple sclerosis and Alzheimer’s still largely a mystery, their inherent variability is hard to account for. The best way to combat the problem? Break trial design down into more manageable pieces....
As it was starting to get cold in the Northeast, a group of us snowbirded down to warm Florida for the CNS Summit. Before the conference began, we participated in STARR Coalition’s annual meeting. STARR Coalition is a remarkable group whose mission is to create meaningful change by increasing communication, partnerships, and goodwill among stakeholders...
DURHAM, N.C., October 28, 2016 — STARR Coalition, an organization dedicated to treatment, advocacy, research, and recovery in mental health, named Premier Research CRO of the Year at its annual STARR Meeting in Boca Raton, Florida. The group cited Premier Research for its longstanding partnership in supporting the coalition’s mission to serve the mental health...
DURHAM, N.C., October 26, 2016 — Premier Research’s lead strategist will participate in a panel discussion on the evolving landscape for investigator sites at CNS Summit 2016 in Boca Raton, Florida. Krista Armstrong, Vice President of Strategic Development, will join colleagues in addressing topics such as: Advantages and disadvantages of site consolidation Site selection and strategic...